Evidence map›Paper›PMID 33156452›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2021

Early Gastric Cancer: identification of molecular markers able to distinguish submucosa-penetrating lesions with different prognosis.

Chiara Molinari, Gianluca Tedaldi, Francesca Rebuzzi, Paolo Morgagni, Laura Capelli, Sara Ravaioli, Maria Maddalena Tumedei, Emanuela Scarpi, Anna Tomezzoli, Riccardo Bernasconi and 8 more

Open access · bronzeAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Genomic events stratifying prognosis of early gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024
    Article
  4. Article
  5. Circulating Proteins as Diagnostic Markers in Gastric Cancer.International journal of molecular sciences · 2023
    Review
  6. International journal of molecular sciences · 2023
    Article
  7. High Frequency of Microsatellite Instability among Non-Metastatic Gastric Cancer.International journal of hematology-oncology and stem cell research · 2022
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Chiara MolinariBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, 47014, Meldola, FC, Italy.
Gianluca TedaldiBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, 47014, Meldola, FC, Italy. gianluca.tedaldi@irst.emr.it.ORCID http://orcid.org/0000-0003-0540-6694
Francesca RebuzziBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, 47014, Meldola, FC, Italy.
Paolo MorgagniDepartment of Surgery, Morgagni-Pierantoni Hospital, Forlì, Italy.
Laura CapelliBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, 47014, Meldola, FC, Italy.
Sara RavaioliBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, 47014, Meldola, FC, Italy.
Maria Maddalena TumedeiBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, 47014, Meldola, FC, Italy.
Emanuela ScarpiBiostatistics and Clinical Trials Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Anna TomezzoliDepartment of Pathology, University of Verona, Verona, Italy.
Riccardo BernasconiDepartment of Pathology, University of Verona, Verona, Italy.
Maria Raffaella AmbrosioPathology Unit, University of Siena, Siena, Italy.
Alessia D'IgnazioSurgery Unit, University of Siena, Siena, Italy.
Leonardo SolainiDepartment of Surgery, Morgagni-Pierantoni Hospital, Forlì, Italy.
Francesco LimarziBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, 47014, Meldola, FC, Italy.
Giorgio ErcolaniDepartment of Surgery, Morgagni-Pierantoni Hospital, Forlì, Italy.
Giovanni MartinelliDepartment of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Paola Ulivi *Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, 47014, Meldola, FC, Italy.
Luca Saragoni *Pathology Unit, Morgagni-Pierantoni Hospital, Forlì, Italy.
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITOspedale G.B. Morgagni - L.Pierantoni · ITUniversity of Siena · ITUniversity of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEarly Gastric Cancer (EGC) reaches 25% of the gastric cancers surgically treated in some areas of Northeastern Italy and is usually characterized by a good prognosis. However, among EGCs classified according to Kodama's criteria, Pen A subgroup is characterized by extensive submucosal invasion, lymph node metastases and worse prognosis, whereas Pen B subgroup by better prognosis. The aim of the study was to characterize the differences between Pen A, Pen B and locally advanced gastric cancer (T3N0) in order to identify biomarkers involved in aggressiveness and clinical outcome.

methodsWe selected 33 Pen A, 34 Pen B and 20 T3N0 tumors and performed immunohistochemistry of mucins, copy number variation analysis of a gene panel, microsatellite instability (MSI), TP53 mutation and loss of heterozygosity (LOH) analyses.

resultsPen A subgroup was characterized by MUC6 overexpression (p = 0.021). Otherwise, the Pen B subgroup was significantly associated with the amplification of GATA6 gene (p = 0.002). The higher percentage of MSI tumors was observed in T3N0 group (p = 0.002), but no significant differences between EGC types were found. Finally, TP53 gene analysis showed that 32.8% of Pen tumors have a mutation in exons 5-8 and 50.0% presented LOH. Co-occurrence of TP53 mutation and LOH mainly characterized Pen A tumors (p = 0.022).

conclusionsOur analyses revealed that clinico-pathological parameters, microsatellite status and frequency of TP53 mutations do not seem to distinguish Pen subgroups. Conversely, the amplification of GATA6 was associated with Pen B, as well as the overexpression of MUC6 and the TP53

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorDNA Copy Number VariationsEarly Detection of CancerFemaleGastric MucinsGastric MucosaHumansImmunohistochemistryItalyLoss of HeterozygosityLymphatic MetastasisMaleMicrosatellite InstabilityBiomarkers, TumorGastric MucinsTP53 protein, humanTumor Suppressor Protein p53Early Gastric CancerGATA6MUC6Submucosa-penetrating tumorsTP53

Identifiers

PMID33156452
OpenAlexW3095110575

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.